IGM Biosciences to Present at Four Upcoming Investor Conferences

Rhea-AI Summary

IGM Biosciences, a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer will present at four investor conferences in September 2020. The conferences include:

• Baird 2020 Global Healthcare Conference on September 9 at 3:10 p.m. ET
• H.C. Wainwright 22^nd Annual Global Investment Conference on September 16 at 1:00 p.m. ET
• 2020 Cantor Global Virtual Healthcare Conference on September 17 at 4:40 p.m. ET
• Morgan Stanley 18th Annual Global Healthcare Conference on September 18 at 11:45 a.m. ET

Live webcasts will be available on the company's website with a 90-day archive.

MOUNTAIN VIEW, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at four upcoming investor conferences:

• Baird 2020 Global Healthcare Conference on Wednesday, September 9 at 3:10 p.m. ET.
• H.C. Wainwright 22^nd Annual Global Investment Conference on Wednesday, September 16 at 1:00 p.m. ET.
• 2020 Cantor Global Virtual Healthcare Conference on Thursday, September 17 at 4:40 p.m. ET.
• Morgan Stanley 18th Annual Global Healthcare Conference on Friday, September 18 at 11:45 a.m. ET.

A live webcast of the events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcasts will be archived on the Company’s website for 90 days following the event.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

FAQ

What conferences will IGM Biosciences present at in September 2020?

IGM Biosciences will present at four conferences: Baird 2020 Global Healthcare Conference on September 9, H.C. Wainwright 22nd Annual Global Investment Conference on September 16, Cantor Global Virtual Healthcare Conference on September 17, and Morgan Stanley 18th Annual Global Healthcare Conference on September 18.

Who is presenting for IGM Biosciences at the investor conferences?

Fred Schwarzer, the Chief Executive Officer of IGM Biosciences, will present at the upcoming investor conferences.

Where can I watch the IGM Biosciences conference presentations?

The presentations can be watched live on the 'Events and Presentations' page in the 'Investors' section of IGM Biosciences' website.

How long will the IGM Biosciences conference webcasts be available for replay?

The conference webcasts will be archived on the IGM Biosciences website for 90 days following each event.

What is the focus of IGM Biosciences as a company?

IGM Biosciences is focused on creating and developing engineered IgM antibodies for therapeutic use.